COYA Stock Recent News
COYA LATEST HEADLINES
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Dr. Stanley H. Appel, Professor of Neurology, Houston Methodist Hospital will participate in a BTIG hosted KOL webcast “Is Alzheimer's next for GLP-1s and Combos?” on February 27, 2025 to discuss the potential treatment of Al.
Coya Therapeutics, Inc. has Treg therapies for neurodegenerative and autoimmune diseases, targeting ALS, FTD, AD, and PD. However, their lead candidate is now clearly COYA 302. This drug basically combines low-dose IL-2 and CTLA4-Ig, and it's now progressing toward Phase 2 trials for ALS and FTD. COYA 301 was intended for AD, but its mixed Phase 2 results may be why COYA is now pivoting toward COYA 302.
Potential initiation of phase 2b study using COYA-302 for the treatment of patients with Amyotrophic Lateral Sclerosis, expected in 2025 barring successful IND clearance by the FDA. Biomarker data from proof-of-concept study using COYA-302 for the treatment of patients with Amyotrophic Lateral Sclerosis, expected in Q2 of 2025. The global Amyotrophic Lateral Sclerosis market is expected to reach $1.33 billion by 2033.
On Thursday, Coya Therapeutics, Inc. COYA announced blood biomarker data from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of LD IL-2 in patients with Alzheimer's disease (AD).
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announced encouraging blood biomarker data from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of LD IL-2 in patients with Alzheimer's disease (AD). Statistically significant reduced levels of proinflammatory markers were observed in patients.
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that five of eight patients have been enrolled in the investigator-initiated academic study of LD IL-2 + CTLA4-Ig combination in patients with Frontotemporal Dementia (FTD). The study is being conducted by Drs. Stanley Appel and Alireza Faridar at Houston Methodist Hospital. Toplin.
Coya Therapeutics is developing treatments for neurodegenerative diseases, with its lead drug COYA 302 showing promising early results in ALS trials. Despite recent delays, the adverse investor reaction presents an investment opportunity as the company progresses on its pipeline development. The partnership with Dr. Reddy's Labs validates COYA 302 and provides a mechanism for rapid commercial scaling upon FDA approval.
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chairman and CEO Howard Berman, Ph.D. has been recognized as a PharmaVoice 100 winner in the category of Biotech Pathfinders. The annual list recognizes the most inspiring people in the life sciences industry and is a another recognition of Dr. Berman's impact as Coya's CEO as.
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function announces that data from the IIT, a double-blind, placebo-controlled, phase 2 clinical trial of interleukin-2 (IL-2) in patients with mild to moderate Alzheimer's Disease, conducted at Houston Methodist Research Institute and supported by the Gates Foundation and the Alzheimer's Association w.
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the expansion of its research collaboration with the Houston Methodist Research Institute (“HMRI”) through a sponsored research agreement (SRA) covering multiple initiatives. The development and production of exosomes from patients' regulatory T cells will be funded by the Johnson.